Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Jun 26

PMID 26110819

Citations 11

Authors

Andreas Agathangelidis

Lydia Scarfo

Federica Barbaglio

Benedetta Apollonio

Maria Teresa Sabrina Bertilaccio

Pamela Ranghetti

Maurilio Ponzoni

Gabriella Leone

Valeria De Pascali

Lorenza Pecciarini

Paolo Ghia

Federico Caligaris-Cappio

Cristina Scielzo

Affiliations

Soon will be listed here.

Abstract

Immortalized cell lines representative of chronic lymphocytic leukemia (CLL) can assist in understanding disease pathogenesis and testing new therapeutic agents. At present, very few representative cell lines are available. We here describe the characterization of a new cell line (PCL12) that grew spontaneously from the peripheral blood (PB) of a CLL patient with progressive disease and EBV infection. The CLL cell origin of PCL12 was confirmed after the alignment of its IGH sequence against the "original" clonotypic sequence. The IGH gene rearrangement was truly unmutated and no CLL-related cytogenetic or genetic lesions were detected. PCL12 cells express CD19, CD20, CD5, CD23, low levels of IgM and IgD and the poor-outcome-associated prognostic markers CD38, ZAP70 and TCL1. In accordance with its aggressive phenotype the cell line is inactive in terms of LYN and HS1 phosphorylation. BcR signalling pathway is constitutively active and anergic in terms of p-ERK and Calcium flux response to α-IgM stimulation. PCL12 cells strongly migrate in vitro in response to SDF-1 and form clusters. Finally, they grow rapidly and localize in all lymphoid organs when xenotrasplanted in Rag2-/-γc-/- mice. PCL12 represents a suitable preclinical model for testing pharmacological agents.

Citing Articles

culture of leukemic cells in collagen scaffolds and carboxymethyl cellulose-polyethylene glycol gel.

Svozilova H, Vojtova L, Matulova J, Bruknerova J, Polakova V, Radova L PeerJ. 2024; 12:e18637.

PMID: 39655330 PMC: 11627079. DOI: 10.7717/peerj.18637.

CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity.

Imbery J, Wiik C, Heinzelbecker J, Jebsen J, Dobbing M, Bottini N Mol Ther Oncol. 2024; 32(3):200841.

PMID: 39474602 PMC: 11519781. DOI: 10.1016/j.omton.2024.200841.

Cyclic Fasting-Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia.

Raucci F, Vernieri C, Di Tano M, Ligorio F, Blazevits O, Lazzeri S Cancer Res. 2024; 84(7):1133-1148.

PMID: 38241703 PMC: 10982641. DOI: 10.1158/0008-5472.CAN-23-0295.

Toll-like receptor 9 signaling in chronic lymphocytic leukemia cell lines.

Meloni M, Sana I, Mantione M, Riba M, Muzio M FEBS Open Bio. 2023; 13(12):2367-2374.

PMID: 37881888 PMC: 10699106. DOI: 10.1002/2211-5463.13726.

Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.

Aroldi A, Mauri M, Ramazzotti D, Villa M, Malighetti F, Crippa V J Cell Mol Med. 2023; 27(20):3053-3064.

PMID: 37654003 PMC: 10568669. DOI: 10.1111/jcmm.17868.

References

Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S . From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2009; 10(1):37-50. DOI: 10.1038/nrc2764. View

Rasul E, Salamon D, Nagy N, Leveau B, Banati F, Szenthe K . The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia. PLoS One. 2014; 9(8):e106008. PMC: 4146575. DOI: 10.1371/journal.pone.0106008. View

Mockridge C, Potter K, Wheatley I, Neville L, Packham G, Stevenson F . Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood. 2007; 109(10):4424-31. DOI: 10.1182/blood-2006-11-056648. View

Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D . MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res. 1999; 23(2):127-36. DOI: 10.1016/s0145-2126(98)00154-4. View

Lanemo Myhrinder A, Hellqvist E, Bergh A, Jansson M, Nilsson K, Hultman P . Molecular characterization of neoplastic and normal "sister" lymphoblastoid B-cell lines from chronic lymphocytic leukemia. Leuk Lymphoma. 2013; 54(8):1769-79. DOI: 10.3109/10428194.2013.764418. View

Apollonio B, Scielzo C, Bertilaccio M, Ten Hacken E, Scarfo L, Ranghetti P . Targeting B-cell anergy in chronic lymphocytic leukemia. Blood. 2013; 121(19):3879-88, S1-8. DOI: 10.1182/blood-2012-12-474718. View

Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T . Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 2007; 21(12):2442-51. DOI: 10.1038/sj.leu.2404935. View

Balatti V, Rizzotto L, Miller C, Palamarchuk A, Fadda P, Pandolfo R . TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2015; 112(7):2169-74. PMC: 4343115. DOI: 10.1073/pnas.1500010112. View

Hallek M, Cheson B, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-56. PMC: 2972576. DOI: 10.1182/blood-2007-06-093906. View

10.

Stevenson F, Forconi F, Packham G . The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia. Semin Hematol. 2014; 51(3):158-67. DOI: 10.1053/j.seminhematol.2014.05.003. View

11.

Scott D, Gascoyne R . The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014; 14(8):517-34. DOI: 10.1038/nrc3774. View

12.

Ten Hacken E, Scielzo C, Bertilaccio M, Scarfo L, Apollonio B, Barbaglio F . Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia. Blood. 2013; 121(12):2264-73. DOI: 10.1182/blood-2012-09-457119. View

13.

Burger J, Tsukada N, Burger M, Zvaifler N, DellAquila M, Kipps T . Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000; 96(8):2655-63. View

14.

Gaidano G, Foa R, Dalla-Favera R . Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012; 122(10):3432-8. PMC: 3461921. DOI: 10.1172/JCI64101. View

15.

Rickinson A, Finerty S, Epstein M . Interaction of Epstein-Barr virus with leukaemic B cells in vitro. I. Abortive infection and rare cell line establishment from chronic lymphocytic leukaemic cells. Clin Exp Immunol. 1982; 50(2):347-54. PMC: 1536694. View

16.

Apollonio B, Bertilaccio M, Restuccia U, Ranghetti P, Barbaglio F, Ghia P . From a 2DE-gel spot to protein function: lesson learned from HS1 in chronic lymphocytic leukemia. J Vis Exp. 2014; (92):e51942. PMC: 4353291. DOI: 10.3791/51942. View

17.

Byrd J, Furman R, Coutre S, Burger J, Blum K, Coleman M . Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015; 125(16):2497-506. PMC: 4400288. DOI: 10.1182/blood-2014-10-606038. View

18.

Hadzidimitriou A, Darzentas N, Murray F, Smilevska T, Arvaniti E, Tresoldi C . Evidence for the significant role of immunoglobulin light chains in antigen recognition and selection in chronic lymphocytic leukemia. Blood. 2008; 113(2):403-11. DOI: 10.1182/blood-2008-07-166868. View

19.

Bertilaccio M, Scielzo C, Simonetti G, Ten Hacken E, Apollonio B, Ghia P . Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. Leukemia. 2012; 27(3):534-40. DOI: 10.1038/leu.2012.268. View

20.

Simons A, Shaffer L, Hastings R . Cytogenetic Nomenclature: Changes in the ISCN 2013 Compared to the 2009 Edition. Cytogenet Genome Res. 2013; 141(1):1-6. DOI: 10.1159/000353118. View